# Novo Nordisk (NVO) — Earnings

NVO · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/nvo/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.78 |
| EPS estimate | $0.80 |
| EPS surprise | −2.73% |
| Revenue surprise | −0.02% |
| Revenue | $11.0B |
| Revenue estimate | $11.0B |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/353278/000117184326005172/f6k_080426.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/5ec17782-b2b2-4371-2b54-2258ee9fa04a.html) |

Novo Nordisk reported Q2 2026 results on August 4, 2026. Earnings per share were $0.78, missing the $0.80 estimate by 2.73%. Revenue was $11.0 billion, in line with the $11.0 billion consensus. Compared with Q2 2025, EPS fell about 16% from $0.93 and revenue fell about 8% from $12.0 billion. It was the second straight quarter of lower revenue year over year.

The longer record shows strong growth that has slowed. Annual EPS rose from $1.69 in 2022 to $2.72 in 2023, $3.24 in 2024 and $3.56 in 2025, with yearly gains shrinking from about 61% to 19% and then 10%. Quarterly revenue doubled from $5.5 billion in Q3 2021 to a high of $12.5 billion in Q4 2025. Q1 2026 holds the EPS high in the table at $1.04. The first half of 2026 adds up to $1.82 per share, about 5% less than a year earlier. Novo Nordisk beat EPS estimates in 15 of the last 20 quarters.

Novo Nordisk reported Q3 between November 2 and November 6 in each of the past four years. That points to early November 2026 for the next report. It will show whether the year-over-year declines of the first half continue.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | $0.80 | $0.78 | -2.73% | $11.0B | $11.0B |
| Q1 2026 | May 6, 2026 | $0.91 | $1.04 | 14.35% | $10.9B | $11.0B |
| Q4 2025 | Feb 3, 2026 | $0.93 | $0.95 | 3.06% | $12.1B | $12.5B |
| Q3 2025 | Nov 5, 2025 | $0.76 | $0.69 | -9.41% | $11.9B | $11.5B |
| Q2 2025 | Aug 6, 2025 | $0.92 | $0.93 | 1.02% | $11.9B | $12.0B |
| Q1 2025 | May 7, 2025 | $0.91 | $0.99 | 8.78% | $11.7B | $11.9B |
| Q4 2024 | Feb 5, 2025 | $0.83 | $0.89 | 6.56% | $11.1B | $12.0B |
| Q3 2024 | Nov 6, 2024 | $0.88 | $0.88 | 0.19% | $10.6B | $10.3B |
| Q2 2024 | Aug 7, 2024 | $0.71 | $0.66 | -7.04% | $10.0B | $10.0B |
| Q1 2024 | May 2, 2024 | $0.75 | $0.81 | 8.33% | $9.1B | $9.4B |
| Q4 2023 | Jan 31, 2024 | $0.67 | $0.72 | 6.77% | $9.2B | $9.6B |
| Q3 2023 | Nov 2, 2023 | $0.68 | $0.71 | 4.57% | $8.2B | $8.4B |
| Q2 2023 | Aug 10, 2023 | $0.68 | $0.64 | -5.87% | $8.2B | $8.0B |
| Q1 2023 | May 4, 2023 | $0.62 | $0.65 | 4.31% | $7.7B | $7.9B |
| Q4 2022 | Feb 1, 2023 | $0.42 | $0.43 | 2.57% | $6.8B | $6.9B |
| Q3 2022 | Nov 2, 2022 | $0.41 | $0.42 | 3.27% | $5.9B | $6.0B |
| Q2 2022 | Aug 3, 2022 | $0.41 | $0.40 | -2.71% | $5.7B | $5.6B |
| Q1 2022 | Apr 29, 2022 | $0.42 | $0.44 | 4.21% | $5.8B | $6.0B |
| Q4 2021 | Feb 2, 2022 | $0.36 | $0.36 | 1.35% | $5.8B | $5.8B |
| Q3 2021 | Invalid Date | $0.39 | $0.41 | 5.66% | $5.4B | $5.5B |

## Frequently Asked Questions

### When did Novo Nordisk (NVO) last report earnings?

Novo Nordisk last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did NVO beat earnings estimates?

No. Novo Nordisk reported EPS of $0.78 for Q2 2026 against a $0.80 estimate — a 2.73% miss.

### How much revenue did NVO report last quarter?

Novo Nordisk reported $11.0B in revenue for Q2 2026, against a consensus estimate of $11.0B.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).